Key result
Fentanyl may impair the antiplatelet action of ticagrelor, potentially increasing the risk of thrombotic complications in patients with coronary artery disease.
Why the study?
Recent findings suggest fentanyl may impair ticagrelor action and risk thrombotic complications in coronary artery disease, but the underlying mechanism and biological effects on platelets remain poorly understood.
Does fentanyl impair the action of ticagrelor in patients with coronary artery disease?
Design
Review article
Authors
Loading...
May warrant caution with fentanyl in ticagrelor-treated CAD patients; leaves open confirmation of clinical thrombotic impact.
Does fentanyl impair the action of ticagrelor in patients with coronary artery disease?
Fentanyl may interact with ticagrelor, potentially leading to insufficient platelet inhibition and increased risk of thrombotic complications in patients with coronary artery disease.
Kuçzyńska et al. (2020) conducted a review in Coronary artery disease. Fentanyl was evaluated. Fentanyl may impair the antiplatelet action of ticagrelor, potentially increasing the risk of thrombotic complications in patients with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: